CTLA4 and renal cell carcinoma: Toxicity from TKI or mTOR inhibitors for RCC and from chemotherapy, BRAF inhibitors or anti-CTLA-4 antibodies for melanoma are low-grade but continuous and exert a negative impact on quality of life.